# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10567225
Filing Date		2006-02-03
First Named Inventor Tobia		s Helbig
Art Unit		2618
Examiner Name		
Attorney Docket Number		DE030265

				U.S.	PATENTS	Remove		
Examiner Initial*	Cite No Patent Number		Kind Code <sup>1</sup>	Issue Date Name of Patentee or Applicant			Columns,Lines where nt Passages or Relevant Appear	
	1	5515509		1996-05-07	ROM			
	2	5933420		1999-08-03	JASZEWSKI ET AL			
	3	6208629	B1	2001-03-27	JASZEWSKI ET AL			
	4	6496490	B1	2002-12-17	ANDREWS ET AL			
If you wis	h to a	dd additional U.S. Pater	t citatio	n information pl	lease click the Add button.		Add	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Releva	Columns,Lines where nt Passages or Relevant Appear	
	1	20020075835	A1	2002-06-20	KRISHNAKUMAR ET AL			
	2	20030053437	A1	2003-03-20	BAHL ET AL			

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10567225
Filing Date		2006-02-03
First Named Inventor Tobia		s Helbig
Art Unit		2618
Examiner Name		
Attornou Docket Number		DE030265

								_		
	3	20030063592	A1	2003-04	1-03	SEKI ET AL				
If you wish	h to a	dd additional U.S. Publ	ished Ap	plication	citatio	information	please click the Ado	butto	1. Add	_
				FOREIG	SN PAT	ENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Countr Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patentee Applicant of cited Document	or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
	1	9517724	wo		A1	1995-06-29	MAHANY			
	2	0180500	WO WO EP		A2	2001-10-25	HILLS ET AL			
	3	02091788			A2	2002-11-14	SUZUKI ET AL			
	4	1257092			A1	2002-11-13	BUSCH ET AL			
	5	1387596	EP		A1	2004-04-20	SUZUKI ET AL			
If you wis	h to a	dd additional Foreign P	atent Do	cument	citation	information p	lease click the Add	button	Add	
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove	
Examiner Initials*	Cite No	Include name of the a (book, magazine, jour publisher, city and/or	nal, seri	al, symp	osium,	catalog, etc),				T5
	1 XUE ET AL, "Basestation Collaboration in Bluelooth Voice Networks", Computer Networks 41, 2003, pages 289-301									
If you wis	you wish to add additional non-patent literature document citation information please click the Add button Add									

# | Application Number | 10567225 | Filing Date | 2006.02.43 | | STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) | Art Unit | 2818 | | Examiner Name | Attorney Docket Number | DE030265 |

	EXAMINER SIGNATURE								
Examiner Signature		Date Considered							
	reference considered, whether or not citation is in conformation and not considered. Include copy of this form with								

See Kin Codes of USPTO Patent Documents at Invent/ISPTO.GOV or MPEP 801.04. Enter of tice that issued the document, by the how-let of KinPD Standard ST3.) For Lapraces patent document, the notice under the patent document patent of the parent of the Empirer name process the serial running report and the Empirer name process the serial running of the Empirer name process the serial running and the Ser

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10567225
Filing Date		2006-02-03
First Named Inventor Tobias		is Helbig
Art Unit		2618
Examiner Name		
Attorney Docket Numb	er	DE030265

### CERTIFICATION STATEMENT

Please see	37	CFR	1 97	and	1 QR tv	make th	e sporo	nnista	coloction/s	e)·

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/3/(40.)

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

V Nor

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Aaron M. Waxler/	Date (YYYY-MM-DD)	2007-02-08
Name/Print	Aaron Waxler	Registration Number	48,027

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Pleatert and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1445, Alexandrin, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandria, V.S. 2311-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.